SecBot SecBot
COURT-RULING ·Filed Jun 16, 2026

MRNA

Moderna, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago CourtCourt Ruling · courtlistener.com
Court ruling (district)
Actionable Insight • Neutral

This is a routine procedural ruling with no material impact on Moderna's stock. The underlying patent litigation continues on its existing schedule. Monitor for claim construction rulings or summary judgment motions later in 2026, which would carry substantive risk.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$61.80
T+0 close · Jun 17, 2026 · via day close
Latest settled
+137.36%
T+60 · $146.69
Vs SPY
+134.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $61.80entry
  2. T+1 · 5mo ago +3.50%α +2.46% · $63.96
  3. T+5 · 5mo ago −3.32%α −2.67% · $59.75
  4. T+20 · 4mo ago +0.03%α −0.54% · $61.82
  5. T+60 · 2mo ago +137.36%α +134.41% · $146.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A Special Master in the District of Delaware denied GSK's motion to limit third-party inventor depositions to 10 combined hours across its patent infringement cases against Pfizer/BioNTech and Moderna. The ruling allows each defendant group up to 7 hours per inventor witness, preserving full examination rights for key inventors Dr. Geall and Dr. Mandl. This is a procedural discovery ruling with no financial exposure, no injunction, and no change to the underlying patent litigation merits.

Court Ruling Details

Ruling Date
Jun 8, 2026
Court
United States District Court for the District of Delaware
Court Level
District
Judge
Special Master Monté T. Squire
Case Type
patent
Ruling Type
procedural
Outcome
WIN: ruling favors this company
Precedent Risk
LOW

Key Facts

  • GSK's motion to limit defendants to 10 combined hours of third-party inventor depositions was DENIED
  • Each defendant group (Pfizer/BioNTech and Moderna) retains the right to up to 7 hours per inventor witness under FRCP 30(d)(1)
  • The ruling concerns two key witnesses: Dr. Andrew Geall (named inventor on all asserted patents) and Dr. Christian Mandl
  • Fact discovery closes July 29, 2026, in all three related actions
  • No damages, injunction, or liability determination was made, purely a scheduling/discovery dispute

Financial Impact

No financial impact, procedural discovery ruling only

Risk Factors

  • No new risks from this ruling, the underlying patent infringement cases remain pending with no liability determination

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
13% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-3rrqn0ol-MRNA

Track record

26 reports on MRNA

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
  2. Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
  3. Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
  6. Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
  8. Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  9. Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
  10. Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published Jun 17, 2026